Takara Bio Europe partner with Boston IVF Fertility Centre selectscience.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from selectscience.net Daily Mail and Mail on Sunday newspapers.
Danish spin-out PanCryos has reached a licensing agreement with Takara Bio Europe AB (TBEAB) surrounding its clinical-grade human embryonic stem (hES) cell lines. Click to read more.
Takara Bio Europe AB & PanCryos Announce Agreement to Enable Development of Cell-Based Therapy for Diabetes
Takara Bio Europe AB & PanCryos Announce Agreement to Enable Development of Cell-Based Therapy for Diabetes
26 May 2021Science
Takara Bio Europe AB (TBEAB) and PanCryos are pleased to announce that they have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucose-responsive beta cells and is one of several customers in TBEAB’s new out-licensing program, which enables industrial partners to use the clinical-grade hES cells to develop and commercialize breakthrough cell therapy products for previously unmet indications. Jacqueline Ameri, CEO of PanCryos said, We are very hopeful that our extensive scientific and industry expertise, combined with TBEAB’s expertise in clinical-grade hES cell production, will put us in a position
Search jobs 05-May-2021 Takara Bio Europe AB and PanCryos Announce Licensing Agreement to Enable Development of Cell-Based Therapy for Diabetes
Göteberg, Sweden May 05, 2021
Life Science Newswire – Takara Bio Europe AB (TBEAB) and PanCryos are pleased to announce that they have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucose-responsive beta cells and is one of several customers in TBEAB’s new out-licensing program, which enables industrial partners to use the clinical-grade hES cells to develop and commercialize breakthrough cell therapy products for previously unmet indications. Jacqueline Ameri, CEO of PanCryos said, “We are very hopeful that our extensive scientific and industry expertise, combined with TBEAB’s expertise in clinical-grade hES cell production, will